In particular, we demonstrated that selective blockade of β3-AR on TILs reduced IFN-γ secretion, which in turn decreased the PD-L1 expression on NB tumor cells promoting an immune-reactive TME. The gene discussed is ADRB3; the disease is neuroblastoma.